Have you been paying attention to shares of Rockwell Medical (RMTI) ? Shares have been on the move with the stock up 83.1% over the past month. The stock hit a new 52-week high of $3.43 in the previous session. Rockwell Medical has gained 71.4% since the start of the year compared to the 11.8% move for the Zacks Medical sector and the 12.8% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't miss ...

Have you been paying attention to shares of Rockwell Medical (RMTI) ? Shares have been on the move with the stock up 34.4% over the past month. The stock hit a new 52-week high of $2.64 in the previous session. Rockwell Medical has gained 36.5% since the start of the year compared to the 9.5% move for the Zacks Medical sector and the 8.4% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than the traditional "buying low and selling high" strategy, aiming for quicker profits [1] Group 1: Momentum Investing Characteristics - Momentum investing can be risky as stocks may lose momentum if their valuations exceed future growth potential, leading to potential losses for investors [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Rockwell Medical (RMTI) Analysis - Rockwell Medical (RMTI) has shown significant recent price momentum with a four-week price change of 16.5%, indicating growing investor interest [4] - RMTI has gained 30.4% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [5] - The stock has a beta of 1.43, suggesting it moves 43% more than the market in either direction, indicating fast-paced momentum [5] - RMTI holds a Momentum Score of A, suggesting it is an opportune time to invest in the stock [6] Group 3: Earnings Estimates and Valuation - RMTI has received a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which typically attract more investor interest [7] - The stock is currently trading at a Price-to-Sales ratio of 0.78, indicating it is undervalued as investors pay only 78 cents for each dollar of sales [7] - This favorable valuation suggests that RMTI has significant potential for further price appreciation [8]

( ) ROCKWELL MEDICAL Investor Presentation August 8, 2024 Nasdaq Listed Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2024, 2025 and 2026 guidance, future net sales, reliance on capital investments, ability to grow, industry leadership position, total addressable estim ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President & Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President-Finance Conference Call Participants Ram Selvaraju - H.C. Wainwright Anthony Venditti - Maxim Group Operator Good morning, and welcome to Rockwell Medical's Second Quarter 2024 Results Conference Call and Webcast. Please note, this eve ...

Rockwell Medical (RMTI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 125%. A quarter ago, it was expected that this maker of products used in the treatment of kidney disease and anemia would post a loss of $0.05 per share when it actually produced a loss of $0.02, delivering ...

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its ch ...

Rockwell's Current Market Opportunity Rockwell's May 14, 2024 Investor Presentation Rockwell's May 14, 2024 Investor Presentation Rockwell's stock has been trending upwards since about February, but even at its current price, the company still trades for just ~.7x its trailing twelve months' sales total. Why the Present Discounted Valuation May be Persisting and Risks to this Thesis Finviz Synopsis Rockwell is an Indispensable Player Onfoated to manufanication in the scalability and transportation As shown ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President, Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President, Finance Conference Call Participants Ram Selvaraju - H.C. Wainwright Anthony Vendetti - Maxim Group Operator Good morning, and welcome to Rockwell Medical's First Quarter 2024 Results Conference Call and Webcast. Please note, this event ...

Rockwell Medical (RMTI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this maker of products used in the treatment of kidney disease and anemia would post a loss of $0.08 per share when it actually produced earnings of $0.02, delivering a surprise o ...